Abstract
When caused by multiplication mutations of its gene, increased expression of α-synuclein is associated with familial parkinsonism. Here we discuss the possibility that other mechanisms of α-synuclein elevation contribute to the pathogenesis of idiopathic, sporadic Parkinsons disease and other human synucleinopathies. Environmental (e.g. toxic exposures) and genetic (e.g. gene polymorphisms) risk factors, on the background of normal aging, are likely to enhance vulnerability to neurodegenerative processes. Current evidence suggests that an increased level of neuronal α-synuclein may represent a key pathogenetic event common to these risk factors. Higher protein expression could underlie a gain of toxic properties of α-synuclein (e.g. enhanced tendency to aggregate) that predispose and/or directly contribute to neuronal demise. An important corollary to this latter concept is that a promising therapeutic approach against Parkinsons and other neurodegenerative diseases is to prevent α-synuclein accumulation. Means to achieve this include (i) the use of RNA interference to suppress α-synuclein expression, (ii) the induction of neuronal pathways of protein degradation (e.g. macroautophagy) involved in α-synuclein clearance, and (iii) the development of anti-aggregation agents counteracting the formation of toxic oligomeric or fibrillar forms of the protein.
Keywords: α-synuclein, Parkinson's disease, substantia nigra, aggregation, neurotoxins, aging, RNA interference, autophagy
Current Protein & Peptide Science
Title: Enhanced α-Synuclein Expression in Human Neurodegenerative Diseases: Pathogenetic and Therapeutic Implications
Volume: 10 Issue: 5
Author(s): Alison L. McCormack and Donato A. Di Monte
Affiliation:
Keywords: α-synuclein, Parkinson's disease, substantia nigra, aggregation, neurotoxins, aging, RNA interference, autophagy
Abstract: When caused by multiplication mutations of its gene, increased expression of α-synuclein is associated with familial parkinsonism. Here we discuss the possibility that other mechanisms of α-synuclein elevation contribute to the pathogenesis of idiopathic, sporadic Parkinsons disease and other human synucleinopathies. Environmental (e.g. toxic exposures) and genetic (e.g. gene polymorphisms) risk factors, on the background of normal aging, are likely to enhance vulnerability to neurodegenerative processes. Current evidence suggests that an increased level of neuronal α-synuclein may represent a key pathogenetic event common to these risk factors. Higher protein expression could underlie a gain of toxic properties of α-synuclein (e.g. enhanced tendency to aggregate) that predispose and/or directly contribute to neuronal demise. An important corollary to this latter concept is that a promising therapeutic approach against Parkinsons and other neurodegenerative diseases is to prevent α-synuclein accumulation. Means to achieve this include (i) the use of RNA interference to suppress α-synuclein expression, (ii) the induction of neuronal pathways of protein degradation (e.g. macroautophagy) involved in α-synuclein clearance, and (iii) the development of anti-aggregation agents counteracting the formation of toxic oligomeric or fibrillar forms of the protein.
Export Options
About this article
Cite this article as:
McCormack L. Alison and Di Monte A. Donato, Enhanced α-Synuclein Expression in Human Neurodegenerative Diseases: Pathogenetic and Therapeutic Implications, Current Protein & Peptide Science 2009; 10 (5) . https://dx.doi.org/10.2174/138920309789351912
DOI https://dx.doi.org/10.2174/138920309789351912 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
Call for Papers in Thematic Issues
Advancements in Proteomic and Peptidomic Approaches in Cancer Immunotherapy: Unveiling the Immune Microenvironment
The scope of this thematic issue centers on the integration of proteomic and peptidomic technologies into the field of cancer immunotherapy, with a particular emphasis on exploring the tumor immune microenvironment. This issue aims to gather contributions that illustrate the application of these advanced methodologies in unveiling the complex interplay ...read more
Nutrition and Metabolism in Musculoskeletal Diseases
The musculoskeletal system consists mainly of cartilage, bone, muscles, tendons, connective tissue and ligaments. Balanced metabolism is of vital importance for the homeostasis of the musculoskeletal system. A series of musculoskeletal diseases (for example, sarcopenia, osteoporosis) are resulted from the dysregulated metabolism of the musculoskeletal system. Furthermore, metabolic diseases (such ...read more
Protein Folding, Aggregation and Liquid-Liquid Phase Separation
Protein folding, misfolding and aggregation remain one of the main problems of interdisciplinary science not only because many questions are still open, but also because they are important from the point of view of practical application. Protein aggregation and formation of fibrillar structures, for example, is a hallmark of a ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Brain Slices as Models for Neurodegenerative Disease and Screening Platforms to Identify Novel Therapeutics
Current Neuropharmacology Targeting Kynurenine 3-Monooxygenase (KMO): Implications for Therapy in Huntingtons Disease
CNS & Neurological Disorders - Drug Targets Neuroferritinopathy: Update on Clinical Features and Pathogenesis
Current Drug Targets A Case of Akathisia induced by Escitalopram: Case Report & Review of Literature
Current Drug Safety Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Autism Spectrum Disorders: Etiology and Pharmacotherapy
Current Drug Therapy The Other Side of Opioid Receptor Signalling: Regulation by Protein-Protein Interaction
Current Drug Targets The Effects of Nanoencapsulated Curcumin-Fe3O4 on Proliferation and hTERT Gene Expression in Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Adenosine A2A Receptor Antagonists and Parkinsons Disease: State of the Art and Future Directions
Current Pharmaceutical Design A Review of the Current Clinical Use of Quetiapine and Extended Release Quetiapine in the Management of Anxiety and Related Disorders
Current Psychopharmacology Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives
CNS & Neurological Disorders - Drug Targets The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism COMMENTARY: Magnetic Resonance Techniques Applied to Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Meet Our Associate Editorial Board Member
Current Psychopharmacology GABAB Receptors as Potential Therapeutic Targets
Current Drug Targets - CNS & Neurological Disorders Positive Allosteric Modulators (PAMs) of Metabotropic Glutamate Receptor 5 (mGluR5) Attenuate Microglial Activation
CNS & Neurological Disorders - Drug Targets Subject Index to Volume 4
Current Topics in Medicinal Chemistry Transgenic Mouse Models of Tauopathy in Drug Discovery
CNS & Neurological Disorders - Drug Targets Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity
Current Medicinal Chemistry